Dr. Ye is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Avenue
Houston, TX 77030Phone+1 832-748-6369- Is this information wrong?
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015- Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2009 - 2012
Wayne State University School of MedicineResidency, Internal Medicine, 2009 - 2012
Shanghai Jiao Tong University School of MedicineClass of 1993
Certifications & Licensure
TX State Medical License 2022 - 2025
MI State Medical License 2009 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.Amro M Stino, Naresh Bumma, Rachel Smith, Long Davalos, Jeff Allen, Jing Christine Ye, Matthew Pianko, Erica Campagnaro, Cassandra Fierro, Abdelrahman Awad, Ben Murdoc...> ;European Journal of Neurology. 2024 Mar 1
- 17 citationsThe genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.Josh N Vo, Yi-Mi Wu, Jeanmarie Mishler, Sarah Hall, Rahul Mannan, Lisha Wang, Yu Ning, Jin Zhou, Alexander C Hopkins, James C Estill, Wallace K B Chan, Jennifer Yesil,...> ;Nature Communications. 2022 Jun 29
- 23 citationsThe role of biomarkers in personalized immunotherapy.Kamya Sankar, Jing Christine Ye, Zihai Li, Lei Zheng, Wenru Song, Siwen Hu-Lieskovan> ;Biomarker Research. 2022 May 18
- Join now to see all
Abstracts/Posters
- Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with RituximabJ Christine Ye, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...J Christine Ye, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Associate
Hospital Affiliations
University of Michigan Medical CenterAnn Arbor, Michigan
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
